GenNext Technologies earns the coveted $250,000 Grand Prize Award at the 2022 BioTools Innovator Final CompetitionOctober 26, 2022
Company will use the award to further develop scientific instruments, software, and services that ultimately improve the safety, stability, and effectiveness of biotherapeutics
GenNext Technologies, Inc., a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers, today announced that it received the 2022 Grand Prize Award in the BioTools Innovator competition.
BioTools Innovator is the largest life science accelerator in the world, supported by founding partners Research Corporation Technologies and BroadOak Capital Partners. GenNext, chosen amongst a field of 160 emerging life science tools companies, will receive $250K in non-dilutive funding, along with access to an elite ecosystem of mentors, peers, and investors to help ensure the continued growth of GenNext Technologies and the success of its customers in biopharmaceutical discovery and development.
Scot Weinberger, CEO of GenNext Technologies, commented, “Not only did we gain $250,000 in non-dilutive funding, but BioTools has and will continue to open the doors to an elite group of mentors, partners, and investors over the months and years to come.” Scot went on to say, “This accolade further establishes GenNext as a true rising star in the life science tools space. This BioTools experience has given us a platform to convey our mission and value to BioPharma, and we are proud to say that GenNext is here to transform how researchers perform protein therapeutic Higher Order Structure (HOS) analysis using our novel Hydroxyl Radical Protein Footprinting (HRPF) tools, resulting in more effective and safer biopharmaceuticals.”
GenNext secured the award during the final pitch session held at the BioTools Innovator Capstone Event on October 13, in Carlsbad, Calif. Along with the live audience, the five finalists were judged by leading investors, manufacturing and service providers, and strategic partners in the life science tools space including Agilent, Thermo Fisher Scientific, BroadOak Capital Partners, Northpond Ventures, and Illumina Ventures.
GenNext is addressing an important unmet need with its novel Flash Oxidation (Fox™) Protein Footprinting System comprised of instrumentation, consumables, software, and services for biopharmaceutical researchers investigating protein structure, interactions, folding, aggregation, formulation, and delivery.
This award will enable GenNext to accelerate its efforts to make structural biology research easier and more insightful. “By thoughtfully and strategically deploying this award in R&D and commercial operations, and seeking the counsel of our new BioTools network, we can make the study of protein HOS more accessible, safe, and accurate for our customers,” stated Dr. Joshua Sharp, GenNext's Chief Technology Officer.
About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, compact, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug therapies that improve human health.
Corporate, Finance & Investor